<DOC>
	<DOCNO>NCT00418704</DOCNO>
	<brief_summary>The purpose study determine duration progression first-line treatment chemotherapy follow erlotinib second-line compare erlotinib first-line follow chemotherapy second-line old patient none small cell lung cancer .</brief_summary>
	<brief_title>Elderly Independent Patients With Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>A multicenter phase II trial , prospective , randomize , open , non comparative</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age &gt; 65 year Comorbidities score , PS frailty score**.according ( TABLE N°1 ) No dementia , repeat fall , faecal urinary incontinence , ADL=0 , IADL=0 Life expectancy least 12 week Créatinine clearance de la créatinine &gt; =30cc/mn accord Cockrofts Gault formula Competency give write informed consent Haematological function follow : absolute neutrophil count &gt; 1.5 x 109/l and/or platelet &gt; 100 x 109/l , hémoglobine &gt; = 9,5 g/dl Hepatic function follow : bilirubin &lt; 1,25 LNS SGOT/SGPT &lt; 5 x N , PAL &lt; 5N PS &lt; 3 No symptomatic cerebral metastasis Histologically cytologically confirm NSCLC Stage IV/IIIB4 ( T4with pleural effusion ) No prior chemotherapy NSCLC Relapses previous NSCLC treat surgery radiotherapy eligible target measurable initial radiotherapy field histological cytological proof At least one measurable target lesion RECIST guideline . Symptomatic cerebral metastasis Any severe comorbidity calculate Charlson score ( accord table 1 ) , kind disorder compromise ability subject give write informed and/or comply study procedure ADL &gt; = 1 et IADL &gt; =1 Dementia , repeat fall , faecal urinary incontinence Peripheral neuropathy grade 2 Performance Status &gt; 2 ( ECOG ) Contraindication corticosteroid Unwilling unable comply study requirement personal , family , sociologic , geographic reason Lack liberty follow administrative judicial decision Hypersensitivity polysorbate Hypersensitivity erlotinib excipients product Unusual hereditary disorder galactosemia , deficit lactase malabsorption glucose galactose Participation concomitant clinical trial Contraindication product study disease Bronchioloalvéolar neuroendocrine composite carcinoma Superior vena cava syndrome</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>None small-cell lung cancer</keyword>
</DOC>